Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/26952
Title: | Measuring the dose in bone for spine stereotactic body radiotherapy. | Austin Authors: | Shaw, Maddison;Lye, Jessica ;Alves, Andrew;Hanlon, Maximilian;Lehmann, Joerg;Supple, Jeremy;Porumb, Claudiu;Williams, Ivan;Geso, Moshi;Brown, Rhonda | Affiliation: | Institute of Medical Physics, University of Sydney, Australia School of Science, RMIT University, Melbourne, Australia School of Mathematical and Physical Sciences, University of Newcastle, Australia Australian Clinical Dosimetry Service, Australian Radiation Protection and Nuclear Safety Agency, Melbourne, Australia Primary Standards Dosimetry Laboratory, ARPANSA, Melbourne, Australia School of Health and Biomedical Sciences, RMIT University, Melbourne, Australia. Olivia Newton-John Cancer Wellness and Research Centre Alfred Health Radiation Oncology, The Alfred Hospital, Melbourne, Australia Australian Radiation Protection and Nuclear Safety Agency, Melbourne, Australia School of Health and Biomedical Sciences, RMIT University, Melbourne, Australia Department of Radiation Oncology, Calvary Mater Newcastle, Newcastle, Australia |
Issue Date: | Apr-2021 | Date: | 2021-03-25 | Publication information: | Physica Medica : PM 2021; 84: 265-273 | Abstract: | Current quality assurance of radiotherapy involving bony regions generally utilises homogeneous phantoms and dose calculations, ignoring the challenges of heterogeneities with dosimetry problems likely occurring around bone. Anthropomorphic phantoms with synthetic bony materials enable realistic end-to-end testing in clinical scenarios. This work reports on measurements and calculated corrections required to directly report dose in bony materials in the context of comprehensive end-to-end dosimetry audit measurements (63 plans, 6 planning systems). Radiochromic film and microDiamond measurements were performed in an anthropomorphic spine phantom containing bone equivalent materials. Medium dependent correction factors, kmed, were established using 6 MV and 10 MV Linear Accelerator Monte Carlo simulations to account for the detectors being calibrated in water, but measuring in regions of bony material. Both cortical and trabecular bony material were investigated for verification of dose calculations in dose-to-medium (Dm,m) and dose-to-water (Dw,w) scenarios. For Dm,m calculations, modelled correction factors for cortical and trabecular bone in film measurements, and for trabecular bone in microDiamond measurements were 0.875(±0.1%), 0.953(±0.3%) and 0.962(±0.4%), respectively. For Dw,w calculations, the corrections were 0.920(±0.1%), 0.982(±0.3%) and 0.993(±0.4%), respectively. In the audit, application of the correction factors improves the mean agreement between treatment plans and measured microDiamond dose from -2.4%(±3.9%) to 0.4%(±3.7%). Monte Carlo simulations provide a method for correcting the dose measured in bony materials allowing more accurate comparison with treatment planning system doses. In verification measurements, algorithm specific correction factors should be applied to account for variations in bony material for calculations based on Dm,m and Dw,w. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/26952 | DOI: | 10.1016/j.ejmp.2021.03.011 | Journal: | Physica Medica : PM | PubMed URL: | 33773909 | Type: | Journal Article | Subjects: | Dose to medium Dosimetry Dosimetry audit Quality assurance SBRT |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.